Celgene Corporation (CELG) : Eaton Vance Management scooped up 315,440 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 2,834,758 shares of Celgene Corporation which is valued at $322,623,808.Celgene Corporation makes up approximately 0.90% of Eaton Vance Management’s portfolio.
Other Hedge Funds, Including , Allegis Investment Advisors boosted its stake in CELG in the latest quarter, The investment management firm added 613 additional shares and now holds a total of 5,523 shares of Celgene Corporation which is valued at $628,573. Celgene Corporation makes up approx 0.30% of Allegis Investment Advisors’s portfolio.Garrison Bradford Associates Inc reduced its stake in CELG by selling 400 shares or 0.54% in the most recent quarter. The Hedge Fund company now holds 73,270 shares of CELG which is valued at $8,509,578. Celgene Corporation makes up approx 8.02% of Garrison Bradford Associates Inc’s portfolio.Btc Capital Management reduced its stake in CELG by selling 429 shares or 1.21% in the most recent quarter. The Hedge Fund company now holds 34,933 shares of CELG which is valued at $4,057,119. Celgene Corporation makes up approx 0.86% of Btc Capital Management’s portfolio.Pggm Investments boosted its stake in CELG in the latest quarter, The investment management firm added 287,603 additional shares and now holds a total of 373,679 shares of Celgene Corporation which is valued at $40,398,437. Celgene Corporation makes up approx 0.20% of Pggm Investments’s portfolio.
Celgene Corporation opened for trading at $112.17 and hit $112.84 on the upside on Wednesday, eventually ending the session at $112.55, with a gain of 0.34% or 0.38 points. The heightened volatility saw the trading volume jump to 37,33,670 shares. Company has a market cap of $87,239 M.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.